Questions to Ask About Childhood Cancer Treatment

Almost every good question depends on one thing: the precise diagnosis. Not "leukemia," but which leukemia, which subtype, which risk group, and which genetic markers were found.

St. Jude's list of questions for newly diagnosed families starts here, with two openers worth using word for word:

• "What type of cancer does my child have?"
• "Can you explain my child's pathology report (laboratory test results) and imaging results (such as CT, MRI, PET scan) to me?"

Ask for the pathology report on paper. Ask someone to read it with you and mark the line that names the diagnosis. Childhood cancers are sorted into risk groups, and the group often decides how long treatment runs and how intense it is. If a marker is still pending, ask which one, and what each possible answer would change.

Write the exact wording down. You will repeat it to a school nurse, an insurer, and an emergency department clerk, probably in the same week.

NCI says children are usually treated at children's cancer centers, meaning hospitals or units with pediatric cancer expertise. The team there is deliberately mixed: pediatric oncologists, surgical specialists, nurses, and psychologists working together.

Many of these centers belong to the Children's Oncology Group, which NCI supports and describes as the world's largest organization running clinical research to improve care for children with cancer.

So ask two direct questions. Is this center a Children's Oncology Group site? And how many children with this diagnosis does this team treat in a year?

Ask for the treatment roadmap. Most pediatric protocols are built in named phases, and a printed roadmap turns an overwhelming year into a sequence you can see.

Questions St. Jude recommends here:

• "What are my child's treatment options?"
• "What treatment plan do you recommend? Why?"
• "What is the goal of each treatment? Is it to eliminate the cancer, help my child feel better, or both?"
• "When will my child begin treatment?"
• "What else needs to happen before my child can begin treatment?"
• "How long will it take to give this treatment?"
• "Will my child need any special devices to help deliver therapies?"

That last one is about a central line or port, a tube or small device placed in a vein for medicine and blood draws. Ask which type is planned, why that one, when it is placed, and who trains you to care for it.

Then ask what the calendar looks like. How many days a month at the hospital? How many overnight stays are expected? Which visits can happen at a clinic closer to home?

Parents often hear "clinical trial" and think experiment of last resort. In pediatric oncology that framing is backwards.

NCI states that most of the progress in finding curative therapies for childhood cancers has come through clinical trials. The results show it. NCI reports that cancer death rates for children under 15 fell by 70 percent from 1970 through 2020, and that by 2020 there were nearly 496,000 childhood cancer survivors in the United States.

Ask early, before the plan is set:

• Is there an open trial for this diagnosis, here or at another center?
• What is the standard treatment this trial is compared with?
• What extra visits, tests, or biopsies does the trial require?
• Who pays for what?
• If we say no, does anything about our care change?

Ask about tumor genetic testing too. NCI's Pediatric MATCH study reported that 24 percent of young patients with advanced cancer whose tumors were tested for genetic changes qualified for one of the targeted drugs being studied.

For a child under 18, a parent or guardian gives informed permission. The child gives assent, meaning their own agreement to take part. NCI notes that assent may begin around age 7, depending on the child's maturity and understanding.

Informed consent is a process, not a signature. NCI describes it as the research team explaining the trial before you decide, in language you can follow, with time for questions. You may leave a study at any time, even after signing.

Two structures protect trial participants. An institutional review board, or IRB, reviews the trial before it can enroll anyone and again each year. Many trials also have a data and safety monitoring board of independent experts who watch results as they come in and can stop the study if there is a serious concern.

Ask for the consent document overnight. Reading it at the kitchen table beats reading it in a clinic room while a child cries.

These are two different conversations, and both belong in the first week.

For the near term, St. Jude suggests asking what the short-term side effects of each treatment are, and what can be done to relieve them. Add the ones that shape daily life: hair loss, mouth sores, nausea, low blood counts, steroid mood swings, and how each is managed at home.

For the long term, ask these:

• "What are possible long-term side effects? What effects may appear later in my child's life?"
• "Will the treatment affect my child's normal growth and development?"
• "Could this treatment affect my child's ability to become pregnant or have children?"

Then get specific, because these numbers drive follow-up care for decades. Ask for the planned total dose of any anthracycline chemotherapy in milligrams per square meter. Ask whether radiation is planned, where it will be aimed, and at what dose in gray. Ask whether any alkylating agents are included. Write the answers in the same notebook as the diagnosis.

Most fertility preservation options must happen before the first dose of chemotherapy. That makes this the one topic you cannot save for later.

Ask on day one whether treatment carries fertility risk, and ask for a referral to a fertility specialist. Ask whether treatment can safely wait the days that preservation would take. For a child who has not gone through puberty, ask specifically whether an ovarian or testicular tissue freezing protocol is available, here or elsewhere.

St. Jude's list closes with three that families tend to skip:

• "Who can help me with managing the costs of my child's treatment?"
• "What support services are available to my child? To my family?"
• "Whom should we call with questions or problems?"

Ask the third one twice: once for business hours, once for 2 a.m. Get the after-hours number written down, not described. Ask what to say when you call so you reach the oncology fellow rather than a general line.

Add school. Ask for a written letter listing restrictions, and ask who at the hospital helps with school plans.

St. Jude puts the second-opinion question directly on its list: "Should I seek a second opinion? Can you help me obtain a second opinion?"

Asking your child's oncologist to help arrange one is not an insult, and for rare tumors it is routine. Ask how many days a second opinion would add, and whether treatment can safely start while the review happens. Often it can.

• Bring two people. One listens, one writes.
• Ask permission to record. Most teams say yes.
• Bring five written questions and ask the most important one first.
• End with: "What is the one thing you would want me to remember from today?"
• Ask for the plain-language handout or printout on the way out.

See Childhood Cancer Overview and Where Children with Cancer Are Treated for background, and Clinical Trials for Children for trial details. Also useful: Late Effects of Childhood Cancer Treatment, Childhood Cancer Late Effects: Questions for Follow-Up, Returning to School After Cancer, and Helping a Child Take Medicine During Cancer Treatment.

• Childhood Cancers, National Cancer Institute
• Research on Childhood Cancers, National Cancer Institute
• Are Clinical Trials Safe? National Cancer Institute
• Children with Cancer: A Guide for Parents, National Cancer Institute
• Fertility Issues in Girls and Women with Cancer, National Cancer Institute
• Questions to Ask after Childhood Cancer Diagnosis, Together by St. Jude
• Survivorship and Long-Term Follow-Up Guidelines, Children's Oncology Group